Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection
Study sponsor: Armata Pharmaceuticals, Inc. · ARMP
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2024-07-17Actual
Enrollment · participants48Actual
Source updated2026-01-05Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.